nextbiomedical Venture Capital
4 known investors
Find your way into nextbiomedical Venture Capital
NextBiomedical develops innovative polymer-based pharmaceutical and medical device technologies designed to overcome limitations of existing therapeutics. The company specializes in adhesive polymers, polysaccharides, and microparticle formulations for controlled drug delivery and enhanced biocompatibility.
Also known as NextBiomedical · 넥스트바이오메디컬
Investors · 4
Company profile
researched Aug 2026NextBiomedical (넥스트바이오메디컬) is a Korea-based company that develops and commercializes polymer-based therapeutic materials. Its stated focus is on proprietary innovative polymer technologies intended to overcome the limitations of existing treatment materials and to address unmet clinical needs, with an orientation toward combined drug-device (drug-device combination) medical solutions.
The company's technology platform centers on adhesive polymers based on oxidized polysaccharides that physically crosslink on contact with moisture and are described as biodegradable and biocompatible; multifunctional microspheres that rely on physical crosslinking of protein, allow control of in-body degradation time, and are described as uniform and high-performance; and pharmaceutical/medical-device convergence formulations supporting multiple dosage forms, physical drug loading and controlled drug release.
Its product line includes the Nexpowder GI endoscopic hemostasis system, the Nexsphere and Nexsphere-F embolic agents, and NexGel/Guardgel.
▸Full profile — market position, technology, go-to-market, geography
Market position
The company positions itself as a global developer and commercializer of innovative polymer therapeutic materials, stating goals of creating new markets with first-in-class treatment materials, securing clinical evidence toward standard-of-care listing, maintaining global-level development, manufacturing and quality systems with overseas regulatory approval capability, and leveraging distribution agreements with global partners for brand, marketing and network reach.
Technology
The company's core technology consists of adhesive polymers derived from oxidized polysaccharides that undergo physical crosslinking in the presence of moisture and are characterized as biodegradable and biocompatible; multifunctional microspheres formed through physical crosslinking of protein, with adjustable in-body degradation time and uniform, high-performance particle characteristics; and drug/medical-device convergence formulations that permit various dosage forms, physical drug loading and controlled drug release.
Go-to-market
NextBiomedical states that it works with overseas partners and concludes distribution/licensing agreements with global companies, using those partners' brand, marketing and network capabilities to reach world markets, alongside in-house development, manufacturing and quality systems supporting overseas regulatory approvals.
Geography
The company is based in South Korea and describes itself as targeting global markets through overseas partnerships and international regulatory approvals.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
▸Research sources · 1
primary sources listed
- nextbiomedical Venture Capitalnextbiomedical.co.kr · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does nextbiomedical Venture Capital do?
- Korean developer of polymer-based therapeutic materials and drug-device combination products for endoscopic hemostasis and embolization.
- Who are nextbiomedical Venture Capital's investors?
- nextbiomedical Venture Capital's investors include Aju IB Invesment Corporation, IMM Investment Japan, Kiwoom Investment, Solidus Investment.